New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation
Authors:
- 1 October 2020
- journal article
- editorial
- Published by Elsevier in Bulletin du Cancer
- Vol. 107 (10) , 961-962
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical PracticeJAMA Oncology, 2020
- Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic CancerNew England Journal of Medicine, 2019
- Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersGastroenterology, 2019
- Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomesWorld Journal of Gastroenterology, 2018
- Stratégies de maintenance dans les cancers du pancréas avancés : rationnel et enjeuxBulletin du Cancer, 2018
- Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2015